Text Size

Human Dopamine Transported Imaging in Cocaine Abuse: 2 - 2

This study has been completed.
Sponsor:
Collaborator:
Johns Hopkins University
Information provided by:
National Institute on Drug Abuse (NIDA)
ClinicalTrials.gov Identifier:
NCT00000316
First received: September 20, 1999
Last updated: June 23, 2005
Last verified: August 1996
History of Changes
  Purpose

The purpose of this study is to determine the density of DA transporters during prolonged cocaine abuse and during withdrawal from cocaine use. This aim will test the hypothesis that DA transporters are altered by cocaine abuse and reestablished during withdrawal.


Condition Intervention Phase
Cocaine-Related Disorders
 Drug: Cocaine
 Phase 1

Study Type: Interventional
Study Design: Primary Purpose: Treatment
Official Title: Human Dopamine Transported Imaging in Cocaine Abuse: 2

Resource links provided by NLM:

U.S. FDA Resources

Further study details as provided by National Institute on Drug Abuse (NIDA):

Primary Outcome Measures:
  • Psychological effects
  • Effects of investigational drug
  • Physiological changes in: heart rate and blood pre

Estimated Enrollment: 0
Study Start Date: August 1996
Estimated Study Completion Date: December 2001
  Eligibility

Ages Eligible for Study:   21 Years to 45 Years
Genders Eligible for Study:   Male
Accepts Healthy Volunteers:   No
Criteria

Please contact site for information.

  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00000316

Locations
United States, Maryland
Johns Hopkins University
Baltimore, Maryland, United States, 21287
Sponsors and Collaborators
National Institute on Drug Abuse (NIDA)
Johns Hopkins University
Investigators
Principal Investigator: Dean Wong, M.D., Ph.D. Johns Hopkins University
  More Information

No publications provided

ClinicalTrials.gov Identifier: NCT00000316     History of Changes
Other Study ID Numbers: NIDA-09482-2, R01-09482-2
Study First Received: September 20, 1999
Last Updated: June 23, 2005
Health Authority: United States: Federal Government

Additional relevant MeSH terms:
Cocaine-Related Disorders
Substance-Related Disorders
Mental Disorders
Cocaine
Dopamine
Vasoconstrictor Agents
Cardiovascular Agents
Therapeutic Uses
Pharmacologic Actions
Dopamine Uptake Inhibitors
Dopamine Agents
Neurotransmitter Agents
Molecular Mechanisms of Pharmacological Action
 Neurotransmitter Uptake Inhibitors
Physiological Effects of Drugs
Anesthetics, Local
Anesthetics
Central Nervous System Depressants
Sensory System Agents
Peripheral Nervous System Agents
Central Nervous System Agents
Cardiotonic Agents
Sympathomimetics
Autonomic Agents
Protective Agents

ClinicalTrials.gov processed this record on May 16, 2013